These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 37152045)

  • 1. Liquid biopsy in hematological malignancies: current and future applications.
    Talotta D; Almasri M; Cosentino C; Gaidano G; Moia R
    Front Oncol; 2023; 13():1164517. PubMed ID: 37152045
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Circulating Tumor DNA in Diffuse Large B-Cell Lymphoma: from Bench to Bedside?
    Cherng HJ; Herrera A
    Curr Treat Options Oncol; 2024 May; 25(5):659-678. PubMed ID: 38656685
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Blood has never been thicker: Cell-free DNA fragmentomics in the liquid biopsy toolbox of B-cell lymphomas.
    Meriranta L; Pitkänen E; Leppä S
    Semin Hematol; 2023 Jul; 60(3):132-141. PubMed ID: 37455222
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dynamic Treatment Stratification Using ctDNA.
    Vidal J; Taus A; Montagut C
    Recent Results Cancer Res; 2020; 215():263-273. PubMed ID: 31605234
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Circulating Tumor DNA Profiling of a Diffuse Large B Cell Lymphoma Patient with Secondary Acute Myeloid Leukemia.
    Kerle IA; Jägerhuber L; Secci R; Pfarr N; Blüm P; Roesch R; Götze KS; Weichert W; Bassermann F; Ruland J; Winter C
    Cancers (Basel); 2022 Mar; 14(6):. PubMed ID: 35326522
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Circulating Tumor DNA Analysis in Lymphomas].
    Suehara Y
    Gan To Kagaku Ryoho; 2021 Oct; 48(10):1209-1213. PubMed ID: 34657049
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Circulating tumor DNA assisting lymphoma genetic feature profiling and identification.
    Wang H; Wang Z; Zhu S; Li Z; Yang H; Sun P; Zhu M; Zhao X; Shen L; Ou Q; Yang H; Li ZM
    Ann Hematol; 2024 Jul; ():. PubMed ID: 39012515
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serial surveillance by circulating tumor DNA profiling after chimeric antigen receptor T therapy for the guidance of r/r diffuse large B cell lymphoma precise treatment.
    Zhou L; Zhao H; Shao Y; Chen X; Hong R; Wang L; Ni F; Nagler A; Hu Y; Huang H
    J Cancer; 2021; 12(18):5423-5431. PubMed ID: 34405005
    [No Abstract]   [Full Text] [Related]  

  • 9. Cell-free circulating tumor DNA supplementing tissue biopsies for identification of targetable mutations: Implications for precision medicine and considerations for reconciling results.
    Hicks JK; Saller J; Wang E; Boyle T; Gray JE
    Lung Cancer; 2017 Sep; 111():135-138. PubMed ID: 28838384
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Detection of the
    Zorofchian S; Lu G; Zhu JJ; Duose DY; Windham J; Esquenazi Y; Ballester LY
    Front Oncol; 2018; 8():382. PubMed ID: 30294590
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genotyping on ctDNA Identifies Shifts in Mutation Spectrum Between Newly Diagnosed and Relapse/Refractory DLBCL.
    Liu H; Yang C; Zhao X; Le J; Wu G; Wei J; Liang Y; Qian W
    Onco Targets Ther; 2020; 13():10797-10806. PubMed ID: 33122918
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Circulating tumor DNA: clinical roles in diffuse large B cell lymphoma.
    Wu FT; Lu L; Xu W; Li JY
    Ann Hematol; 2019 Feb; 98(2):255-269. PubMed ID: 30368587
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Circulating tumor DNA in Hodgkin lymphoma.
    Maco M; Kupcova K; Herman V; Ondeckova I; Kozak T; Mocikova H; Havranek O;
    Ann Hematol; 2022 Nov; 101(11):2393-2403. PubMed ID: 36074181
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular features encoded in the ctDNA reveal heterogeneity and predict outcome in high-risk aggressive B-cell lymphoma.
    Meriranta L; Alkodsi A; Pasanen A; Lepistö M; Mapar P; Blaker YN; Jørgensen J; Karjalainen-Lindsberg ML; Fiskvik I; Mikalsen LTG; Autio M; Björkholm M; Jerkeman M; Fluge Ø; Brown P; Jyrkkiö S; Holte H; Pitkänen E; Ellonen P; Leppä S
    Blood; 2022 Mar; 139(12):1863-1877. PubMed ID: 34932792
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Circulating tumor DNA predicts response in Chinese patients with relapsed or refractory classical hodgkin lymphoma treated with sintilimab.
    Shi Y; Su H; Song Y; Jiang W; Sun X; Qian W; Zhang W; Gao Y; Jin Z; Zhou J; Jin C; Zou L; Qiu L; Li W; Yang J; Hou M; Xiong Y; Zhou H; Du X; Wang X; Peng B
    EBioMedicine; 2020 Apr; 54():102731. PubMed ID: 32304999
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Distinct biological subtypes and patterns of genome evolution in lymphoma revealed by circulating tumor DNA.
    Scherer F; Kurtz DM; Newman AM; Stehr H; Craig AF; Esfahani MS; Lovejoy AF; Chabon JJ; Klass DM; Liu CL; Zhou L; Glover C; Visser BC; Poultsides GA; Advani RH; Maeda LS; Gupta NK; Levy R; Ohgami RS; Kunder CA; Diehn M; Alizadeh AA
    Sci Transl Med; 2016 Nov; 8(364):364ra155. PubMed ID: 27831904
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prospects for liquid biopsy approaches in lymphomas.
    Jamal E; Poynton E; Elbogdady M; Shamaa S; Okosun J
    Leuk Lymphoma; 2024 Aug; ():1-11. PubMed ID: 39126310
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Circulating tumor DNA: a promising biomarker in the liquid biopsy of cancer.
    Cheng F; Su L; Qian C
    Oncotarget; 2016 Jul; 7(30):48832-48841. PubMed ID: 27223063
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Longitudinal Monitoring of Plasma Circulating Tumour DNA Enables the Prediction of Early Relapse in Patients with Non-Hodgkin Lymphoma: A Case Series.
    Ji H; Long X; Gu J; Jin J; Mao X; Wang Z; Ma H; Chen L
    Diagnostics (Basel); 2021 Nov; 11(11):. PubMed ID: 34829401
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical Utility of Analyzing Circulating Tumor DNA in Patients with Metastatic Colorectal Cancer.
    Nakamura Y; Yoshino T
    Oncologist; 2018 Nov; 23(11):1310-1318. PubMed ID: 29700206
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.